Everett Vokes, MD, is the John E. Ultmann Distinguished Service Professor and Chair of the Department of Medicine at the University of Chicago, and physician-in-chief at the University of Chicago Medicine
Dr. Vokes earned his medical degree at the University of Bonn Medical School in Bonn, Germany. He completed his clerkship at St Luke’s Hospital in Sydney, Australia, and an internship at Malteser Hospital in Bonn. He completed his internship and residency in internal medicine at the Ravenswood Hospital Medical Center in Chicago, a senior residency in internal medicine at the University of Southern California-Los Angeles County Hospital, and a fellowship in hematology-oncology at the University of Chicago.
A clinical and translational investigator, Dr. Vokes focuses on the biology and treatment of lung and head and neck cancers and the interaction of chemotherapy and radiation and integration of targeted and immune-based agents. He established the intellectual and clinical basis of national trials investigating concomitant chemoradiotherapy and other approaches to providing multispecialty care and leads clinical and translational investigations both at the university and nationally.
Dr. Vokes is a member of professional organizations including the American Society of Clinical Oncology, the American Association for Cancer Research, and the International Association for the Study of Lung Cancer, among others. He is an elected member of the American Society of Clinical Investigation and American Association of Professors and serves on the editorial boards of several oncology journals and is a reviewer for various publications.
To his credit are more than 80 book chapters and 500 papers published in such journals as New England Journal of Medicine, Journal of Clinical Oncology, Annals of Oncology, and Journal of Thoracic Oncology, to name a few. Dr. Vokes has presented his work at numerous medical congresses.
Crizotinib versus observation or placebo for surgically resected early-stage ALK-positive non-small-cell lung cancer (Eastern Cooperative Oncology Group-American College of Radiology Imaging Network E4512): a phase 3 trial.
Crizotinib versus observation or placebo for surgically resected early-stage ALK-positive non-small-cell lung cancer (Eastern Cooperative Oncology Group-American College of Radiology Imaging Network E4512): a phase 3 trial. Lancet Respir Med. 2026 Aug 25.
PMID: 42641639
Adjuvant Nivolumab vs Observation in Resected Non-Small Cell Lung Cancer: A Randomized Clinical Trial.
Adjuvant Nivolumab vs Observation in Resected Non-Small Cell Lung Cancer: A Randomized Clinical Trial. JAMA. 2026 Aug 11; 336(6):464-472.
PMID: 42224490
Project Optimus for Radiation Therapy-Drug Combinations: Moving Beyond the Maximum Tolerated Dose.
Project Optimus for Radiation Therapy-Drug Combinations: Moving Beyond the Maximum Tolerated Dose. Int J Radiat Oncol Biol Phys. 2026 Jul 30.
PMID: 42530498
Comprehensive multi-omic dissection and AI-prioritized target identification in inverted papilloma-associated sinonasal squamous cell carcinoma.
Comprehensive multi-omic dissection and AI-prioritized target identification in inverted papilloma-associated sinonasal squamous cell carcinoma. NPJ Precis Oncol. 2026 Jul 10.
PMID: 42432132
Mature Outcomes of 61.2 Gy Concomitant Boost Thoracic Radiation Therapy in Limited-Stage Small Cell Lung Cancer: CALGB 30610 (Alliance)/RTOG 0538.
Mature Outcomes of 61.2 Gy Concomitant Boost Thoracic Radiation Therapy in Limited-Stage Small Cell Lung Cancer: CALGB 30610 (Alliance)/RTOG 0538. Int J Radiat Oncol Biol Phys. 2026 Nov 01; 126(3):727-732.
PMID: 42086125
MDM2 Inhibition with Alrizomadlin (APG-115) in TP53 wild-type salivary gland cancers: a phase I clinical trial.
MDM2 Inhibition with Alrizomadlin (APG-115) in TP53 wild-type salivary gland cancers: a phase I clinical trial. Nat Commun. 2026 Mar 19; 17(1).
PMID: 41857036
Naloxegol, an Oral Peripherally Acting Opioid Receptor Antagonist, Administered Concurrently with First-Line Systemic Therapy for Advanced Lung Adenocarcinoma (Alliance A221504): A Feasibility and Safety Study.
Naloxegol, an Oral Peripherally Acting Opioid Receptor Antagonist, Administered Concurrently with First-Line Systemic Therapy for Advanced Lung Adenocarcinoma (Alliance A221504): A Feasibility and Safety Study. Cancers (Basel). 2026 Jan 25; 18(3).
PMID: 41681846
Tumor-initiating stem cells fine-tune the plasticity of neutrophils to sculpt a protective niche.
Tumor-initiating stem cells fine-tune the plasticity of neutrophils to sculpt a protective niche. Cancer Cell. 2026 Jan 12; 44(1):94-111.e11.
PMID: 41349542
Publisher Correction: Radiation-induced amphiregulin drives tumour metastasis.
Publisher Correction: Radiation-induced amphiregulin drives tumour metastasis. Nature. 2025 Nov; 647(8091):E9.
PMID: 41214352
Early Dynamics of Circulating Tumor HPV-DNA with Neoadjuvant Chemotherapy and Response-Adapted De-escalation in Human Papillomavirus-Associated Oropharyngeal Cancer.
Early Dynamics of Circulating Tumor HPV-DNA with Neoadjuvant Chemotherapy and Response-Adapted De-escalation in Human Papillomavirus-Associated Oropharyngeal Cancer. Clin Cancer Res. 2025 Aug 01; 31(15):3150-3159.
PMID: 40423530